Secondary causes of low bone mass in patients with breast cancer: A need for greater vigilance

Journal of Clinical Oncology

Volumn 27, Issue 22, 2009, Pages 3605-3610

  Mann, G Bruce ^a   Kang, Y Chiu ^a   Brand, Caroline ^a   Ebeling, Peter R ^a   Miller, Julie A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; COLECALCIFEROL; HORMONE RECEPTOR; PARATHYROID HORMONE; VITAMIN D; PTH PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BONE DENSITY; BREAST CANCER; CALCIUM BLOOD LEVEL; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OSTEOPENIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; THYROID FUNCTION TEST; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; AGE; BLOOD; BREAST TUMOR; CANCER STAGING; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; EARLY DIAGNOSIS; HYPERPARATHYROIDISM; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PROGNOSIS; QUESTIONNAIRE; RISK ASSESSMENT;

AGE FACTORS; AGED; BONE DENSITY; BREAST NEOPLASMS; CALCIUM; COHORT STUDIES; COMORBIDITY; EARLY DIAGNOSIS; FEMALE; HUMANS; HYPERPARATHYROIDISM; MIDDLE AGED; NEOPLASM STAGING; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PREVALENCE; PROGNOSIS; QUESTIONNAIRES; RISK ASSESSMENT; VITAMIN D DEFICIENCY;

EID: 68949114597     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.2549     Document Type: Article

References (32)

1. Coleman RE, Banks LM, Girgis SI, et al: Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol 8:119-127, 2007
2. Forbes JF, Cuzick J, Buzdar A, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45-53, 2008
3. Bundred NJ: Optimising bone health in survivors of breast cancer. Lancet Oncol 8:89-91, 2007
4. Bundred NJ, Campbell ID, Davidson N, et al: Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 112:1001-1010, 2008
5. Brufsky A, Harker WG, Beck JT, et al: Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25:829-836, 2007
6. Kelman A, Lane NE: The management of secondary osteoporosis. Best Pract Res Clin Rheumatol 19:1021-1037, 2005
7. Buist DS, LaCroix AZ, Barlow WE, et al: Bone mineral density and breast cancer risk in postmenopausal women. J Clin Epidemiol 54:417-422, 2001
8. Douchi T, Yonehara Y, Kosha S, et al: Bone mineral density in breast cancer patients with positive estrogen receptor tumor status. Maturitas 57:221-225, 2007
9. Fierabracci P, Pinchera A, Miccoli P, et al: Increased prevalence of primary hyperparathyroidism in treated breast cancer. J Endocrinol Invest 24:315-320, 2001
10. Cummings SR, Black DM, Nevitt MC, et al: Bone density at various sites for prediction of hip fractures: The Study of Osteoporotic Fractures Research Group. Lancet 341:72-75, 1993
11. Johnell O, Kanis JA, Oden A, et al: Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185-1194, 2005
12. Pasco JA, Henry MJ, Nicholson GC, et al: Vitamin D status of women in the Geelong Osteoporosis Study: Association with diet and casual exposure to sunlight. Med J Aust 175:401-405, 2001
13. Freedman DM, Looker AC, Chang SC, et al: Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 99:1594-1602, 2007
14. Garland CF, Gorham ED, Mohr SB, et al: Vitamin D and prevention of breast cancer: Pooled analysis. J Steroid Biochem Mol Biol 103:708-711, 2007
15. Gorham ED, Garland CF, Garland FC, et al: Optimal vitamin D status for colorectal cancer prevention: A quantitative meta analysis. Am J Prev Med 32:210-216, 2007
16. Garland CF, Garland FC, Gorham ED, et al: The role of vitamin D in cancer prevention. Am J Public Health 96:252-261, 2006
17. Goodwin PJ, Ennis M, Pritchard KI, et al: Frequency of vitamin D (Vit D) deficiency at breast cancer (BC) diagnosis and association with risk of distant recurrence and death in a prospective cohort study of T1-3, N0-1, M0 B. J Clin Oncol 26:9s, 2008 (suppl; abstr 511)
18. Lappe JM, Travers-Gustafson D, Davies KM, et al: Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. Am J Clin Nutr 85:1586-1591, 2007
19. Christiansen P, Steiniche T, Brixen K, et al: Primary hyperparathyroidism: Short-term changes in bone remodeling and bone mineral density following parathyroidectomy. Bone 25:237-244, 1999
20. Christiansen P, Steiniche T, Brixen K, et al: Primary hyperparathyroidism: Effect of parathyroidectomy on regional bone mineral density in Danish patients - A three-year follow-up study. Bone 25: 589-595, 1999
21. Christiansen P, Steiniche T, Brixen K, et al: Primary hyperparathyroidism: Whole-body bone mineral density in surgically treated Danish patients-A three-year follow-up study. Bone 25:597-602, 1999
22. Lundgren E, Rastad J, Thrufjell E, et al: Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 121: 287-294, 1997
23. Wermers RA, Khosla S, Atkinson EJ, et al: Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: An update on the changing epidemiology of the disease. J Bone Miner Res 21:171-177, 2006
24. Tordjman KM, Greenman Y, Osher E, et al: Characterization of normocalcemic primary hyperparathyroidism. Am J Med 117:861-863, 2004
25. Lundgren E, Ridefelt P, Akerstrom G, et al: Parathyroid tissue in normocalcemic and hypercalcemic primary hyperparathyroidism recruited by health screening. World J Surg 20:727-734, 1996; discussion 735
26. Silverberg SJ, Bilezikian JP: "Incipient" primary hyperparathyroidism: A "forme fruste" of an old disease. J Clin Endocrinol Metab 88:5348-5352, 2003
27. Maruani G, Hertig A, Paillard M, et al: Normocalcemic primary hyperparathyroidism: Evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 88:4641-4648, 2003
28. Cauley JA, Lucas FL, Kuller LH, et al: Bone mineral density and risk of breast cancer in older women: The study of osteoporotic fractures-Study of Osteoporotic Fractures Research Group. JAMA 276:1404-1408, 1996
29. Moseley JM, Kubota M, Diefenbach-Jagger H, et al: Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci U S A 84:5048-5052, 1987
30. Nilsson IL, Zedenius J, Yin L, et al: The association between primary hyperparathyroidism and malignancy: Nationwide cohort analysis on cancer incidence after parathyroidectomy. Endocr Relat Cancer 14:135-140, 2007
31. Almquist M, Manjer J, Bondeson L, et al: Serum calcium and breast cancer risk: Results from a prospective cohort study of 7,847 women. Cancer Causes Control 18:595-602, 2007
32. Perez EA, Josse RG, Pritchard KI, et al: Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA. 17. J Clin Oncol 24:3629-3635, 2006